Table 1.

Cardiovascular immune-related adverse events (irAEs) from use of immune checkpoint inhibitors

Cardiac irAEs	Pembrolizumab	Atezolizumab	Nivolumab	Cemiplimab	Avelumab	Durvalumab
Arrhythmia
Tachycardia	386	178	644	14	31	53
Bradycardia	101	22	144	3	11	10
Miscellaneous	150	34	195	12	9	14
Myocarditis	456	87	704	24	29	62
Pericardial disease	269	81	367	4	10	37
Heart failure	278	98	424	16	14	34
Acute coronary syndrome	187	77	322	10	10	28
Cardiac arrest	123	43	171	3	17	25
Structural cardiac disorders	126	28	134	3	7	16
Total adverse cardiac events	1722	561	2742	76	115	245
Total adverse events	40,805	12,415	62,650	1355	2700	5610

Listed are the most frequently reported adverse cardiac events submitted to VigiAccess (World Health Organization, http://www.vigiaccess.org/ [accessed November 5, 2022]) related to use of various immune checkpoint inhibitors. Miscellaneous arrhythmias include bundle branch blocks, sinus node dysfunction, and pulseless electrical activity. Structural cardiac disorders include cardiomyopathy (excluding ischemic), valvular disease, chamber enlargement, and intracardiac mass.